Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency

Eur J Dermatol. 2021 Feb 1;31(1):93-94. doi: 10.1684/ejd.2020.3954.

Authors

Nicolas Votquenne¹, Gwendy Dupire², Olivier Michel², Benoit Ben Said³

Affiliations

¹ Department of Dermatology.
² Department of Immuno-allergology, CHU Brugmann, Université Libre de Bruxelles (ULB), Belgium.
³ Severe Cutaneous Drug Reaction Reference Centre Dermatology, CHU Lyon, Department of Dermatology, Lyon, France.

PMID: 33586652
DOI: 10.1684/ejd.2020.3954

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Common Variable Immunodeficiency / complications*
Eczema / drug therapy*
Eczema / etiology*
Exanthema / drug therapy*
Exanthema / etiology*
Female
Humans
Middle Aged
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
dupilumab